Neues zu Diagnostik und Therapie des idiopathischen Parkinson-Syndroms

Parkinson-Syndrome zählen zu den häufigsten neurodegenerativen Erkrankungen. Schätzungen beziffern allein die Zahl der Erkrankten, die an einem idiopathischen Parkinson-Syndrom leiden, auf 400000 Menschen in Deutschland. Im Zuge der demografischen Entwicklung wird der Therapie älterer und schwerer Betroffener ein höherer Stellenwert beigemessen werden müssen. In diesem Beitrag sollen die evidenzbasierte Diagnostik und Therapie des idiopathischen Parkinson-Syndroms mit Fokus auf die Behandlung älterer Patient*innen und möglicher Komplikationen dargelegt werden.

• Literatur

• 1 Pringsheim T, Jette N, Frolkis A. et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1583-90
• 2 Moisan F, Kab S, Mohamed F. et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry 2016; 87: 952-957
• 3 Braak H, Braak E, Yilmazer D. et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994; 88: 493-500
• 4 Ruppert MC, Greuel A, Tahmasian M. et al. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain 2020; 143: 944-959
• 5 Costa J, Lunet N, Santos C. et al. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010; 20: S221-S238
• 6 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442
• 7 Postuma RB, Berg D, Stern M. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30: 1591-1601
• 8 Schmidt MA, Engelhorn T, Marxreiter F. et al. Ultra high-field SWI of the substantia nigra at 7T: reliability and consistency of the swallow-tail sign. BMC Neurol 2017; 17 (1): 194. Published 2017;
• 9 Kuebler L, Buss S, Leonov A. et al. [11C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates. Eur J Nucl Med Mol Imaging 2021; 48: 1759-1772
• 10 Skrahina V, Gaber H, Vollstedt EJ. et al. The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings. Mov Disord 2021; 36: 1005-1010
• 11 Verschuur CVM, Suwijn SR, Boel JA. et al. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. N Engl J Med 2019; 380: 315-324
• 12 Stocchi F, Rascol O, Kieburtz K. et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study [published correction appears in Ann Neurol 2010 Sep; 68 (3): 412–3]. Ann Neurol 2010; 68: 18-27
• 13 Fahn S. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 2005; 252 (Suppl. 04) IV37-IV42
• 14 Hauser RA, Mehta SH, Kremens D. et al. Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. Neurol Ther 2021; 10: 739-751
• 15 Deutsche Gesellschaft für Neurologie – DGN. S3-Leitlinie Idiopathisches Parkinson-Syndrom. Leitlinien für Diagnostik und Therapie in der Neurologie DGN. 2016 https://dgn.org/wp-content/uploads/2013/01/030010_LL_langfassung_ips_2016.pdf
• 16 Schuepbach WM, Rau J, Knudsen K. et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368: 610-622
• 17 Antonini A, Odin P, Opiano L. et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm (Vienna) 2013; 120: 1553-1558
• 18 Eggert K, Öhlwein C, Kassubek J. et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014; 37: 116-122
• 19 Pedrosa Carrasco AJ, Timmermann L, Pedrosa DJ. Management of constipation in patients with Parkinson's disease. NPJ Parkinsons Dis 2018; 4: 6
• 20 Reijnders JS, Ehrt U, Weber WE. et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183-313
• 21 Barone P, Poewe W, Albrecht S. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-580
• 22 Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1615-1622
• 23 Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237
• 24 Litvan I, Goldman JG, Tröster AI. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-356
• 25 Emre M, Aarsland D, Albanese A. et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518
• 26 Henderson EJ, Lord SR, Brodie MA. et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 249-258
• 27 Emre M, Tsolaki M, Bonuccelli U. et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977
• 28 Mathis MV, Muoio BM, Andreason P. et al. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. J Clin Psychiatry 2017; 78: e668-e673
• 29 Mueller MC, Jüptner U, Wuellner U. et al. Parkinson's disease influences the perioperative risk profile in surgery. Langenbecks Arch Surg 2009; 394: 511-515